Loading…
iBio, Inc. is projected to rise to $1.58 by 2027, a +4% move from its current price of $1.51. IBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.46 | $1.51 | $1.56 | -0.01% |
| Jul 14 | $1.44 | $1.51 | $1.58 | -0.03% |
| Jul 15 | $1.43 | $1.51 | $1.59 | -0.04% |
| Jul 16 | $1.42 | $1.51 | $1.61 | -0.05% |
| Jul 17 | $1.41 | $1.51 | $1.62 | -0.06% |
| Jul 18 | $1.40 | $1.51 | $1.63 | -0.08% |
| Jul 19 | $1.39 | $1.51 | $1.64 | -0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.39 | $1.51 | $1.64 | -0.09% |
| Week 2 | $1.34 | $1.51 | $1.70 | -0.18% |
| Week 3 | $1.30 | $1.51 | $1.74 | -0.27% |
| Week 4 | $1.27 | $1.50 | $1.78 | -0.36% |
| Week 5 | $1.25 | $1.50 | $1.81 | -0.45% |
| Week 6 | $1.22 | $1.50 | $1.84 | -0.54% |
| Week 7 | $1.20 | $1.50 | $1.87 | -0.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
iBio, Inc. is a preclinical stage biotechnology company that engages in the development of artificial intelligence (AI) antibody solutions for cardiometabolic and obesity space. Its technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases.
The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
iBio, Inc. (IBIO) is a Healthcare sector stock currently priced at $1.52 per share with a market cap of $75.51M. It is ranked 4363 by market capitalization among traded equities. The current price and market position reflect a micro-cap biotechnology name in the healthcare space.
A major floor 18.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 27.8% above — a clean break opens room to run.
A major ceiling 87.4% above — clearing it would confirm fresh momentum.
Key IBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.55 | Sell | $1.55 | Sell |
| MA 10 | $1.63 | Sell | $1.60 | Sell |
| MA 20 | $1.64 | Sell | $1.64 | Sell |
| MA 50 | $1.68 | Sell | $1.73 | Sell |
| MA 100 | $1.96 | Sell | $1.80 | Sell |
| MA 200 | $1.78 | Sell | $1.83 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.11 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -134.17 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -8.48 | Sell |
| Bollinger %B (20,2) | 0.07 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.26 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 15.25 | Buy |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 1.47 | Buy |
| ADX (14) | 13.06 | Neutral |
| ATR (14) | 0.05 | Info |
The sentiment is Bearish in the near term. RSI14 sits at 40, with the price trading below both the 50-day and 200-day moving averages (SMA50 is $1.69 and SMA200 is $1.77). The stock has a nearby support at $1.52 and resistance at $1.93.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.42 | $1.51 | $1.99 | 0% | Neutral | |
| $1.24 | $1.58 | $2.14 | +4% | Neutral | |
| $1.46 | $1.93 | $2.73 | +28% | Bullish | |
| $1.57 | $2.13 | $3.11 | +41% | Bullish | |
| $1.60 | $2.22 | $3.34 | +47% | Bullish | |
| $1.62 | $2.30 | $3.54 | +53% | Bullish | |
| $1.51 | $2.19 | $3.44 | +45% | Bullish | |
| $1.52 | $2.24 | $3.58 | +48% | Bullish | |
| $1.76 | $2.64 | $4.30 | +75% | Bullish | |
| $2.07 | $3.17 | $5.24 | +110% | Bullish | |
| $2.23 | $3.71 | $6.58 | +146% | Bullish | |
| $3.31 | $6.34 | $12.41 | +320% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.42 | $1.51 | $1.81 | +0.00% |
| August 2026 | $1.29 | $1.53 | $1.87 | +1.63% |
| September 2026 | $1.25 | $1.49 | $1.84 | -2.76% |
| October 2026 | $1.20 | $1.45 | $1.81 | -2.84% |
| November 2026 | $1.25 | $1.51 | $1.90 | +4.11% |
| December 2026 | $1.29 | $1.57 | $1.99 | +3.97% |
Click any year to see its month-by-month IBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IBIO price prediction for 2026 points to an average of $1.51 (low $1.42, high $1.99) — a potential gain of 0% on today's $1.51. Price action looks broadly range-bound.
In 2027, IBIO is projected to trade between $1.24 and $2.14, averaging $1.58 — a potential gain of +4% from today's $1.51. That is up +4% on the projected 2026 average. A consolidation phase looks the most probable path here.
iBio, Inc.'s 2028 outlook centres on $1.93, within a $1.46 to $2.73 range. That is up +22% on the projected 2027 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2029, IBIO could reach as high as $3.11, with a base case around $2.13 and support toward $1.57 — roughly +41% from $1.51. Buyers look set to stay in control over this stretch.
Expect IBIO to range from $1.60 to $3.34 through 2030. The $2.22 average target implies a +47% move from current prices. That is up +4% on the projected 2029 average. Momentum favours further upside here.
The IBIO price prediction for 2031 points to an average of $2.30 (low $1.62, high $3.54) — a potential gain of +53% on today's $1.51. Buyers look set to stay in control over this stretch.
In 2032, IBIO is projected to trade between $1.51 and $3.44, averaging $2.19 — a potential gain of +45% from today's $1.51. That is -5% versus the projected 2031 average. Momentum favours further upside here.
iBio, Inc.'s 2033 outlook centres on $2.24, within a $1.52 to $3.58 range. That is up +2% on the projected 2032 average. That marks a +48% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, IBIO could reach as high as $4.30, with a base case around $2.64 and support toward $1.76 — roughly +75% from $1.51. Momentum favours further upside here.
Expect IBIO to range from $2.07 to $5.24 through 2035. The $3.17 average target implies a +110% move from current prices. That is up +20% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The IBIO price prediction for 2040 points to an average of $3.71 (low $2.23, high $6.58) — a potential gain of +146% on today's $1.51. Momentum favours further upside here.
In 2050, IBIO is projected to trade between $3.31 and $12.41, averaging $6.34 — a potential gain of +320% from today's $1.51. That is up +71% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IBIO today (≈ 662.251656 IBIO) could be worth
$4,200.24
+$3,200.24 (+320%) by 2050 · US Dollar
Based on the average projected IBIO price of $6.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IBIOwould be worth at today's price.
$1,000 invested in IBIO on Jul 10, 2025 (≈ 1,204.819301 IBIO) would be worth
$1,819.28
+$819.28 (+81.9%) today · 1.82× · US Dollar
Based on a IBIO entry price of $0.83 vs. today's $1.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.68 | $898.81 | -10.1% |
| 1 month ago | $1.7 | $888.24 | -11.2% |
| 3 months ago | $2.16 | $699.07 | -30.1% |
| 6 months ago | $2.7 | $559.26 | -44.1% |
| 1 year ago | $0.83 | $1,819.28 | +81.9% |
| All time (5.0y) ago | $675 | $2.24 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IBIO forecast.
Our base-case forecast reaches $3.00 around 2035.
Implied market cap at $3.00: $149.04M
The multi-year forecast shows a bullish trajectory after 2027, with the average price rising from $1.52 in 2026 to higher levels in following years. In 2026 the min is $1.42, avg $1.52, max $2.01, with ROI 0 and neutral sentiment; in 2027 the min $1.20, avg $1.54, max $2.11, ROI 1.5 and neutral sentiment. Beginning in 2028 the forecast turns bullish, with 2028 avg $1.88 and 2029 avg $2.07, ROI 23.7% and 36.5% respectively.
The path continues higher, with 2030 avg $2.16 (ROI 42.4%), 2031 avg $2.24 (ROI 47.4%), and 2032 avg $2.08 (ROI 37.1%). By 2034 the average rises to $2.48 (ROI 63.4%), and 2035 to $2.99 (ROI 96.7%). The long-term forecast strengthens further with 2040 avg $3.41 (ROI 124.2%), and 2050 avg $5.81 (ROI 282%).
These figures point to meaningful upside potential, culminating in a 2050 max of $11.65. These are estimates, not guarantees, and depend on multiple factors including development progress and market conditions.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $2.16 with a max of $3.29 and an ROI of 42.4%.
Forecasts show neutral sentiment in 2026 and 2027, turning bullish from 2028 onward with substantial upside through 2050. These are estimates, not guarantees, and should be considered alongside other factors.
The 2040 forecast lists an average of $3.41 and a max of $6.17, with an ROI of 124.2% for the period. A price above $5 is possible in the max scenario for 2040.
Current price is $1.52 and market cap is $75.51M.
Long-term figures show a bullish trajectory with an average price of $5.81 by 2050 and a max of $11.65, corresponding to a 282% ROI in that horizon. These remain estimates and involve risk.
iBio, Inc. Community Discussion
0Share your iBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.